Robert Sanders Williams's most recent trade in Tenaya Therapeutics Inc was a trade of 107,400 Stock Option (Right to buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 107,400 | 107,400 | - | - | Stock Option (Right to buy) | |
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to buy) | |
| Labcorp | Williams Sanders Robert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 8,120 (0%) | 0% | - | Common Stock | |
| Labcorp | Williams Sanders Robert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 236 | - | - | Restricted Stock Unit | |
| Labcorp | Williams Robert Sanders | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 236 | 1,183 | - | - | Restricted Stock Unit | |
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 29,532 | 29,532 | - | - | Stock Option (Right to buy) | |
| Amgen | Robert Sanders Williams | Director | 19 May 2023 | 939 | 6,240 (0%) | 0% | 0 | Common Stock | ||
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 7,173 (0%) | 0% | - | Common Stock | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 849 | - | - | Restricted Stock Unit | |
| Labcorp | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 849 | 1,591 | - | - | Restricted Stock Unit | |
| Amgen | Robert Sanders Williams | Director | 22 Aug 2022 | 200 | 5,301 (0%) | 0% | 250.0 | 49,992 | Common Stock | |
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 39,727 | 39,727 | - | - | Stock Option (Right to buy) | |
| Amgen | Robert Sanders Williams | Director | 23 May 2022 | 600 | 5,501 (0%) | 0% | 250 | 150,000 | Common Stock | |
| Amgen | Robert Sanders Williams | Director | 17 May 2022 | 855 | 6,101 (0%) | 0% | 0 | Common Stock | ||
| Labcorp | Robert Sanders Williams | Director | Sale of securities on an exchange or to another person at price $ 272.98 per share. | 25 Mar 2022 | 572 | 6,431 (0%) | 0% | 273.0 | 156,145 | Common Stock |
| Labcorp | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 742 | 742 | - | - | Restricted Stock Unit | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 771 | 7,003 (0%) | 0% | - | Common Stock | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 771 | 0 | - | - | Restricted Stock Unit | |
| Amgen | Robert Sanders Williams | Director | 18 May 2021 | 837 | 5,246 (0%) | 0% | 0 | Common Stock | ||
| Amgen | Robert Sanders Williams | Director | 07 May 2021 | 250 | 4,409 (0%) | 0% | 251.8 | 62,945 | Common Stock | |
| Amgen | Robert Sanders Williams | Director | 08 Feb 2021 | 250 | 4,659 (0%) | 0% | 238.0 | 59,498 | Common Stock | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 986 | 6,232 (0%) | 0% | - | Common Stock | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 986 | 771 | - | - | Restricted Stock Unit | |
| Labcorp | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 771 | 1,757 | - | - | Restricted Stock Unit | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 1,300 | 0 | - | - | Non-qualified Stock Options | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 98.49 per share. | 26 Jan 2021 | 1,300 | 5,246 (0%) | 0% | 98.5 | 128,037 | Common Stock |
| Labcorp | Robert Sanders Williams | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jan 2021 | 1,149 | 3,946 (0%) | 0% | 0 | Common Stock | |
| Amgen | Robert Sanders Williams | Director | 09 Nov 2020 | 250 | 4,909 (0%) | 0% | 242.4 | 60,600 | Common Stock | |
| Amgen | Robert Sanders Williams | Director | 07 Aug 2020 | 250 | 5,159 (0%) | 0% | 243.0 | 60,738 | Common Stock |